. Author manuscript; available in PMC: 2010 Oct 4.

Published in final edited form as: Pharmacogenomics J. 2009 Jan 27;9(2):127–136. doi: 10.1038/tpj.2008.19

Table 4.

Cytotoxicity expressed as IC₅₀, of oxaliplatin in cells expressing hMATE1 and its genetic variants.

Cell lines	IC₅₀ (μM) ^a	Fold difference compared to MOCK
MOCK	17.8 ± 2.8^b	1.0
hMATE1-Reference	5.1 ± 1.2	3.5
hMATE1-G64D	13.2 ± 2.5^b	1.3
hMATE1-L125F	7.6 ± 1.9	2.3
hMATE1-V338I	6.0 ± 0.17	3.0
hMATE1-V480M	11.7 ± 1.2^b	1.5
hMATE1-C497S	6.3 ± 1.13	2.8
hMATE1-Q519H	7.8 ± 0.38	2.3

IC₅₀ data are from two separate experiments (mean±s.d.). Studies were performed in triplicate in each individual experiment. The fold difference was defined as the ratio of the mean IC₅₀ values in the MOCK cells to that in the hMATE1 reference or variants cells.

P<0.05. Multiple comparisons were analysed using one-way analysis of variance followed by Dunnett’s two-tailed test. hMATE1 reference was used as control.